Cochrane Db Syst Rev
-
Cochrane Db Syst Rev · Nov 2024
Review Meta AnalysisCalcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes.
Maternal nutrition during pregnancy is known to have an effect on fetal growth and development. It is recommended that women increase their calcium intake during pregnancy and lactation, although the recommended dosage varies among professionals. Currently, there is no consensus on the role of routine calcium supplementation for pregnant women other than for preventing or treating hypertension. ⋯ This review indicates that calcium supplementation probably reduces preterm birth before 37 weeks. There are no clear additional benefits to calcium supplementation in preterm birth before 34 weeks or prevention of low birthweight. Large multicentre trials to detect the effect of calcium supplementation on fetal birthweight and preterm birth before 34 weeks as the primary outcomes are needed. Further research into the short- and long-term effects of calcium supplementation would also be beneficial.
-
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of different strategies to minimize blood sampling in preterm infants.
-
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primarily, to determine the effectiveness of a virtual reality (VR) intervention compared to an alternative or no intervention for people living with advanced cancer: on pain intensity, adverse events (AEs) and serious adverse events (SAEs); and secondarily, on additional pain properties (e.g. type, frequency), psychological well-being, other physical symptoms (e.g. anxiety) and quality of life. We will also report on the context in which the VR was implemented (setting, type and dose of VR).
-
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of vaccines to prevent Ebola virus disease in people who have been, or have potentially been, exposed to Ebola virus.
-
Cochrane Db Syst Rev · Nov 2024
Review Meta AnalysisPsychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.
Excessive daytime sleepiness is a common symptom of myotonic dystrophy. Psychostimulants are drugs that are increasingly used to treat hypersomnia in myotonic dystrophy. ⋯ In myotonic dystrophy, the effects of psychostimulants on excessive daytime sleepiness as assessed by the Maintenance of Wakefulness Test or Multiple Sleep Latency Test and on quality of life are very uncertain. Psychostimulants may improve hypersomnia as self-evaluated by the Epworth Sleepiness Scale and may increase the risk of adverse events. More randomised trials are needed to evaluate the efficacy and safety of psychostimulants in both the short and long term.